949-481-1344 Ext. 190
« Back to About Page



Peyman Taeidi established Stemell®, Inc. in 2017 with a synonymous goal to transform the care available to people with major illnesses and disorders. A company, which developed a proprietary and unique way of processing biological allografts, leaded to higher quality products by defining a new standard in this market and having a only one goal in mind to meet-Providing a better, safer and more effective allogeneic product by having the end user in mind-the patients.

A passion for science coupled with a zeal to render medical care easier for patients drove Peyman to start Stemell®, Inc. a revolutionary biotechnology and life science company that provides stem cell technology to millions of people in multiple countries for therapeutic purposes.

After Peyman completed his education in Iran in the field of cellular signaling and epithelial cell polarity, he permanently moved to United States to continue his education and research studies. He graduated with honors from the University of California, Irvine in Cellular Biology and as well as Biological Anthropology. He continued his research in the field of cellular biology and obtained his PhD in cellular signaling and epithelial cellular polarity.

Peyman has drafted more than 7 publications in relation to pancreatic Islet cells. (See Below for References)

His findings and extensive research were mainly targeted at stem cells or cells in general. He drafted 7 publications in islet cells in 2013, recapping his command and legitimacy in research of cells. Peyman has an illustrious career to his credit that amalgamates both theory and practice; important in the field he specializes in. He dedicated a significant amount of time working as a Senior Scientist, process development scientist or scientific advisors at multiple biotechnology company within last 10 years, companies like Johnson and Johnson, Cytori Therapeutics, Prodo Laboratories, Homeland security-Department of public health, Pfizer and Eli Lilly.

He has participated in numerous important projects ( in-vivo and in-vitro) including conducting a research project in biological and genetic aspects of cardiac diseases and also performing in a government funded project called “SCAR” which was designing a process and a device which lead to deliver the ADRC cells (Adipose driven regenerative cells-stem cells) on thermal burn tissues caused by radioactive attacks. This technology resulted in a quicker, more efficient and painless recovery. He was working in governmental research contract calls “SCAR” project as a lead process development scientist. He has been working alongside some of the leading industry professionals, which speaks volumes of his professionalism and performance.

His excellence and confidence at work stems from this acute familiarity with the field he operates in. To top that, he strives to deliver results in a timely manner without compromising quality. His exuberance is infectious and those who work with him praise him for his unfettered determination, compassion and strong work

Peyman established the Stemell corporate with three critical elements in mind, Quality, integrity and commitment.

Publication References

Peer-Reviewed Presentations & Publications:

IPITA 2013 Meeting, Carmel, CA – Sept 25-27, 2013, Oral Presentations:

  1. “Human Islets in Minimal Volume Capsules Utilizing a Novel Glucose Polymer”, Alex Gorkovenko, David Scharp, Gowri Arulmoli, Peyman Taeidi, Eva Albert, Hannah Sunshine, Cory Kucera, Alina Avakian, Daniel McRaney, David Bondurant, Brian Haight, Mike Magaldi, Prodo Laboratories
  2. “Survival and Function of Human Islets Cultured for 4 Weeks PostProcessing  David Scharp, Gowri Arulmoli, Peyman Taeidi, Eva Albert, Alina Avakian, Hannah Sunshine, Cory Kucera, Daniel McRaney, David Bondurant, Brian Haight, Mike Magaldi, Prodo Laboratories
  3. “In vitro Islet Function of Isolated Human Islets from Type 2 Diabetic Donors” David Scharp, Gowri Arulmoli, Peyman Taeidi, Eva Albert, Cory Kucera, Hannah Sunshine, Alina Avakian, Daniel McRaney, David Boundurant, Brian Haight, Mike Magaldi, Prodo Laboratories
  4. “Critical Donor and Processing Variables for Quality Human Islet Recovery” David Scharp, Gowri Arulmoli, Alina Avakian, Peyman Taeidi, Eva Albert, Cory Kucera, Hannah Sunshine, Daniel McRaney, David Bondurant, Brian Haight, Mike Magaldi, Prodo Laboratories
  5. “The Use of Novel Decalin Beads During Collection for Human Islet Preservation and Function” David Scharp, Gowri Arulmoli, Hannah Sunshine, Peyman Taeidi, Eva Albert, Alina Avakian, Cory Kucera, Daniel McRaney, David Bondurant, Brian Haight, Mike Magaldi, Prodo Laboratories
  6. “Multi-Analysis of Islet Culture Variables for Human Islet Culture Optimization” David Scharp, Gowri Arulmoli, Eva Albert, Cory Kucera, Hannah Sunshine, Alina Avakian, Peyman Taeidi, Daniel McRaney, David Bondurant, Brian Haight, Mike Magaldi, Prodo Laboratories
  7.  “Nutrient and Metabolite Documentation for Standardization of Mesenchymal     Stem Cell (MSC) Cultures Using the CEDEX Bio” David W. Scharp, MD, Gowri Arulmoli, Eva Albert, Peyman Taeidi, Hannah Sushine, Cory Kucera, Daniel McRaney, Scharp Technologies


For Medical Professional Viewing Only


Stemell, Inc. does not claim that therapy using StemL products cures or prevents any condition, disease or injury. All statements and opinions provided are for educational and informational purposes only, and we do not diagnose or provide medical or legal advice.

Individuals interested in any cellular or cell-free regenerative medicine therapy are urged to review all pertinent information and do their own research and due diligence before choosing to participate in any therapies. Please consult with your physician for further information and be sure to discuss any potential risks.

Please understand that Stemell, Inc. is a supplier only. Stemell, Inc. is not a sponsor, and Stemell, Inc. is not claiming to cure or treat any disorder or condition.

This site was intended for education purposes only and strictly for use by medical professionals. The FDA recently re-confirmed, there is only one registered stem cell product, and while there is enormous promise in stem cell therapies, and thousands of ongoing experimental applications trying to establish efficacy, these are not at the point where they would meet the scientific standard.

The FDA has stated:
Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.

This site is not intended for consumers.
If you are considering stem cell treatment in the U.S., ask your physician if the necessary FDA approval has been obtained or if you will be part of an FDA-regulated clinical study. This also applies if the stem cells are your own. Even if the cells are yours, there are safety risks, including risks introduced when the cells are manipulated after removal.

“There is a potential safety risk when you put cells in an area where they are not performing the same biological function as they were when in their original location in the body.” Cells in a different environment may multiply, form tumors, or may leave the site you put them in and migrate somewhere else. If you are considering having stem cell treatment in another country, learn all you can about regulations covering the products in that country. Exercise caution before undergoing treatment with a stem cell-based product in a country that—unlike the U.S.—may not require clinical studies designed to demonstrate that the product is safe and effective. FDA does not regulate stem cell treatments used solely in countries other than the United States and typically has little information about foreign establishments or their stem cell products.

Stem cell therapies have enormous promise, but the science in each use is still in the developmental stage. Professional judgment and expertise is needed in using stem cells for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies to consult the national health data bases to evaluate current information from clinical trials and the FDA websites on human tissue should also be consulted to get its current evaluation of any therapy.